Funding for this research was provided by:
sponsored by AIO-Studien gGmbH funded by BMS (AIO-STO-0117)
grants from the State of Baden-Württemberg for “Center of Geriatric Biology and Oncology (ZOBEL) - Perspektivförderung
grants from the State of Baden-Württemberg for “Biology of Frailty - Sonderlinie Medizin”
Medical Faculty Mannheim and the State of Baden-Württemberg
Deutsche Forschungsgemeinschaft within the funding programme Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and Arts and by Ruprecht-Karls-Universität Heidelberg
Received: 18 October 2018
Accepted: 7 March 2019
First Online: 14 March 2019
Ethics approval and consent to participate
: The study was approved by the lead ethics committee of the study, Ethics Committee II at Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany [2017-004F-MA] providing approval for all 34 study sites. The approval was permitted in agreement with local ethics commissions of the participating study sites. Written informed consent for participation is obtained from all participants.
: Not applicable.
: This investigator-initiated trial is sponsored by the non-profit AIO-Studien gGmbH and received funding from Bristol-Myers Squibb (BMS) GmbH & Co. KGaA, NY, USA under study contract.BMS had no role in the study design, and has no role in data collection, management, data analysis and interpretation, or decision to submit results for presentation or publication.NH participated at advisory boards organized by the BMS (presentation incl.), MPE served on advisory board meetings of BMS.The authors report no further conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.